This means that passive immunization with tau antibodies is often a feasible therapeutic goal and that the CSF level of p-tau262/356 or of the microtubule binding area (MTBD) can function a valuable biomarker of tau pathology to monitor tau therapeutics in scientific trials.Their Tale laid the muse for precisely what is shaping up to become a most